Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma
Mené en Asie sur 755 patients atteints d'un cancer de l'estomac ou de la jonction oesogastrique de stade III, cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité de l'ajout de nivolumab à une chimiothérapie adjuvante après une gastrectomie et un curage ganglionnaire
Gastric and gastro-oesophageal junction (GEJ) cancers are a substantial global burden of disease and are among the leading causes of cancer death worldwide. Incremental improvements in patient outcomes have been modest in the past 20 years. Furthermore, survival after surgical resection remains poor. Although geographical differences exist in choice of treatment, there is consensus that for patients with resectable gastric or GEJ cancer, the addition of chemotherapy before or after surgical resection could improve survival.